Premature epiphyseal closure--a complication of etretinate therapy in children.
Two children are described who developed premature epiphyseal closure while receiving etretinate for treatment of congenital hyperkeratotic disorders. The first patient was an 8 1/2-year-old boy with nonbullous ichthyosiform erythroderma who had been on treatment for 6 years, 4 months when premature fusion of the right distal tibial epiphysis was detected. Shortness of stature, thinning of long bones, and traumatic fractures were also observed in this patient. The second child was an 11-year-old girl with systematized verrucous nevi in whom symmetric fusion of both elbow epiphyses and narrowing of the femoral epiphyses bilaterally were noted following treatment with etretinate for 5 years, 5 months.
D000365:Age Determination by Skeleton; D001846:Bone Development / Q000187:drug effects*; D002648:Child; D005050:Etretinate / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000139:chemically induced; D006132:Growth Plate / Q000187:drug effects*; D006801:Humans; D007057:Ichthyosis / Q000188:drug therapy; D008297:Male; D009506:Nevus / Q000188:drug therapy; D010014:Osteolysis / Q000139:chemically induced; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy
D005050:Etretinate